Etimicin Sulfate Sodium Chloride Injection

This product is a semi-synthetic water-soluble antibiotic, belonging to the aminoglycoside class. In vitro antibacterial studies have shown that this product has a wide antibacterial spectrum and has good antibacterial effects on a variety of pathogens, including Escherichia coli, Klebsiella pneumoniae, Enterobacter, Serratia, Proteus mirabilis, Salmonella, Haemophilus influenzae and Staphylococcus, etc. It has certain antibacterial activity against some Pseudomonas and Acinetobacter, etc., and its in vitro MIC value for some gentamicin, micromycin and cefazolin-resistant Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae is still within the blood drug concentration range of the therapeutic dose of this product. It also has certain antibacterial activity against some Staphylococci that produce penicillinase and some low-level methicillin-resistant Staphylococci (MRSA). The mechanism of action of this product is to resist the normal protein synthesis of sensitive bacteria. The results of animal ototoxicity experiments showed that the ototoxicity of this product after intramuscular injection is lower than that of other aminoglycoside antibiotics, and is similar to that of netilmicin.

The main ingredient of this product is ezetimibe sulfate.

It is suitable for various infections caused by sensitive Escherichia coli, Klebsiella pneumoniae, Serratia, Citrobacter, Enterobacter, Acinetobacter, Proteus, Haemophilus influenzae, Pseudomonas aeruginosa and Staphylococcus. Clinical studies have shown that this product has a good effect on the following infections. Respiratory tract infections: such as acute bronchitis, acute exacerbation of chronic bronchitis, community lung infection, etc. Kidney and genitourinary system infections: such as acute pyelonephritis, cystitis, chronic pyelonephritis or acute exacerbation of chronic cystitis, etc. Skin, soft tissue and other infections: such as skin and soft tissue infections, trauma, trauma and postoperative infections and other sensitive bacteria infections.

Intravenous drip. Adults take 0.1~0.15g twice a day (once every 12 hours) for 1 hour. The general course of treatment is 5~10 days.

In some cases, BUN, S-Cr or liver and kidney function indicators such as ALT, AST, and ALP may be slightly elevated, but they return to normal after drug withdrawal. Pharmacological and clinical studies have shown that the ototoxicity and vestibular toxicity of this product are both mild, mainly occurring in patients with renal insufficiency, patients with excessive or overdosage, and manifesting as dizziness, tinnitus, etc., all of which are mild.

Patients who are allergic to this product or other aminoglycoside antibiotics are contraindicated.

This product should not be used in combination with other potentially ototoxic and nephrotoxic drugs such as polymyxin, other aminoglycoside antibiotics, strong uric acid and furosemide (furosemide) to avoid increasing nephrotoxicity and ototoxicity.

Keep tightly closed in a cool, dark place.

250ml: 0.15g of azithromycin (150,000 units) and 2.25g of sodium chloride

Fuan Pharmaceutical Group Ningbo Team Pharmaceutical Co., Ltd.

• Founded in:

  1992-08-12

• Address:

  No. 366, Anping Road, Zhaobaoshan Street, Zhenhai District, Ningbo City, Zhejiang Province

• Tax NO.:

  91330211144072003N

• Registered Funds:

  415 million yuan

• Website:

  Log in to view

• Email:

  Log in to view